Lung Cancer

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for 5 new indications, including melanoma, advanced microsatellite instability-high tumors, and 3 expanded uses in advanced non–small cell lung cancer.

Chul Kim, MD, MPH, discusses the additions of EGFR inhibitors to the lung cancer armamentarium and how to best select therapy for these patients.

Joshua K. Sabari, MD, reflects on the rapidly advancing landscape of lung cancer.

The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer should be atezolizumab and chemotherapy, based on results from the IMpower133 trial.

Michael D. Mix, MD, disucsses the use and optimization of SBRT in the management of patients with early-stage non–small cell lung cancer and oligometastatic disease.

Robert J. Cerfolio, MD, discusses how the use of surgery has significantly evolved over the years and how advances made in robotic surgery improve quality of life of those who need to undergo these procedures.

The FDA has extended the review period for a supplemental biologics license application for single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with a PD-L1 expression level of ≥1% and no EGFR or ALK genomic tumor aberrations.

Amishi Desai, MD, assistant professor of medicine at Upstate University Hospital, discusses the use of immunotherapy in patients with non–small cell lung cancer (NSCLC) with PD-L1 expression less than 1%.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses biomarkers for immune response in non–small cell lung cancer.

Some immune-related adverse events associated with immune checkpoint inhibitor therapies may prove to be higher than the data reported in the trials that led to the drugs’ initial FDA approval.

Amishi Desai, MD, highlights new and emerging data regarding the use of immunotherapy in patients with non–small lung cancer.

Manju P. Paul, MD, assistant professor of medicine at Upstate University Hospital, discusses the pulmonologist’s role as part of the multidisciplinary approach in treating patients with non–small cell lung cancer (NSCLC).

Manju P. Paul, MD, discusses new diagnostic and staging techniques that are advancing standards of care in patients with lung cancer.

Juergen Wolf, MD, medical director, Center for Integrated Oncology, University Hospital of Cologne, Köln Bonn, Köln, Germany, discusses the GEOMETRY study in patients with MET-positive non–small cell lung cancer (NSCLC).

Stephen L. Graziano, MD, discusses available and emerging targeted therapies for common driver mutations in patients with non–small cell lung cancer and the sequencing strategies beyond frontline treatment.

Adham Jurdi, MD, discusses how the updated data from the PACIFIC trial have changed the standard of care for patients with stage III non–small cell lung cancer.

Recent data have moved the needle across the board in oncology, specifically with lung cancer and gastrointestinal cancers, with immunotherapy and targeted agents paving the way for an improvement in survival outcomes.

Over the past 30 years, from the discovery of a fusion rearrangement to the recent promise of LOXO-292, RET targeting has gone from distant concept toward clinical reality.

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, compares liquid and tissue biopsies for the treatment of patients with advanced non–small cell lung cancer.

Nisha A. Mohindra, MD, discusses the current treatment landscape, challenges faced in this patient population, and what she believes will be a focus for further research over the next decade.

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses the FDA approval of atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

The FDA has approved atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer.

The phase III TAHOE trial evaluating second-line rovalpituzumab tesirine as a treatment for patients with advanced small cell lung cancer has stopped enrollment as recommended by an Independent Data Monitoring Committee.

Robert J. Cerfolio, MD, MBA, director, Lung Cancer Center, chief, clinical thoracic surgery, discusses the impact of minimally invasive surgery in the management of non–small cell lung cancer.